Colony Group LLC Exelixis, Inc. Transaction History

Colony Group LLC

$6.66 Billion
Q3 2023

A detailed history of Colony Group LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Colony Group LLC holds 18,290 shares of EXEL stock, worth $620,762. This represents 0.01% of its overall portfolio holdings.

Number of Shares

18,290

Previous 23,790 23.12%

Holding current value

$620,762

Previous $455,000 12.09%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $104,720 - $125,069	-5,500 Reduced 23.12%	18,290 $400,000
Q1 2023 May 16, 2023	BUY	$16.3 - $19.41 $89,650 - $106,755	5,500 Added 30.07%	23,790 $462,000
Q3 2022 Nov 15, 2022	BUY	$15.68 - $22.27 $286,787 - $407,318	18,290 New	18,290 $287,000
Q3 2021 Nov 17, 2021	SELL	$16.3 - $21.14 $2.26 Million - $2.93 Million	-138,538 Closed	0 $0
Q2 2021 Aug 18, 2021	SELL	$17.95 - $25.56 $18,488 - $26,326	-1,030 Reduced 0.74%	138,538 $2.52 Million
Q1 2021 May 21, 2021	SELL	$20.53 - $25.22 $42,989 - $52,810	-2,094 Reduced 1.48%	139,568 $3.15 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $73,210 - $98,728	3,981 Added 2.89%	141,662 $2.84 Million
Q3 2020 Nov 17, 2020	SELL	$20.67 - $26.94 $18,334 - $23,895	-887 Reduced 0.64%	137,681 $3.37 Million
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $32,706 - $54,483	1,987 Added 1.45%	138,568 $3.29 Million
Q1 2020 May 18, 2020	BUY	$14.46 - $21.8 $974,040 - $1.47 Million	67,361 Added 97.31%	136,581 $2.35 Million
Q4 2019 Feb 18, 2020	SELL	$15.15 - $18.89 $923,847 - $1.15 Million	-60,980 Reduced 46.84%	69,220 $1.22 Million
Q3 2019 Nov 26, 2019	BUY	$17.68 - $22.65 $90,875 - $116,420	5,140 Added 4.11%	130,200 $2.3 Million
Q2 2019 Aug 19, 2019	BUY	$18.93 - $24.75 $2.37 Million - $3.1 Million	125,060 New	125,060 $2.67 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Colony Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Colony Group LLC with notifications on news.

Account